152 related articles for article (PubMed ID: 38175344)
1. Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives.
Sabatino V; Pignata A; Valentini M; Fantò C; Leonardi I; Campora M
Cancer Treat Res; 2023; 188():105-147. PubMed ID: 38175344
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review.
Wang Q; Wang X; Yang Y
Gland Surg; 2022 Aug; 11(8):1415-1423. PubMed ID: 36082097
[TBL] [Abstract][Full Text] [Related]
4. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.
Spring LM; Bar Y; Isakoff SJ
J Natl Compr Canc Netw; 2022 Jun; 20(6):723-734. PubMed ID: 35714678
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
7. Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer.
Peterson JR; Cole JA; Pfeiffer JR; Norris GH; Zhang Y; Lopez-Ramos D; Pandey T; Biancalana M; Esslinger HR; Antony AK; Takiar V
Breast Cancer Res; 2023 May; 25(1):54. PubMed ID: 37165441
[TBL] [Abstract][Full Text] [Related]
8. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
Esgueva A; Siso C; Espinosa-Bravo M; Sobrido C; Miranda I; Salazar JP; Rubio IT
J Surg Oncol; 2021 Jan; 123(1):71-79. PubMed ID: 33002230
[TBL] [Abstract][Full Text] [Related]
9. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers.
Crosbie A; Le TK; Zhang Y; Das R; Ades F; Davis C; Gogate A
Future Oncol; 2023 Jan; 19(3):229-244. PubMed ID: 36974619
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives.
Sirico M; Virga A; Conte B; Urbini M; Ulivi P; Gianni C; Merloni F; Palleschi M; Gasperoni M; Curcio A; Saha D; Buono G; Muñoz M; De Giorgi U; Schettini F
Crit Rev Oncol Hematol; 2023 Jan; 181():103900. PubMed ID: 36565894
[TBL] [Abstract][Full Text] [Related]
12. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
13. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
16. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
17. [Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer].
Maráz R; Boross G; Svébis M; Gyánti R; Vizhányó R; Hajnal L; Markó L; Szucs M; Ambrózay E; Lorincz M
Magy Seb; 2005 Aug; 58(4):225-32. PubMed ID: 16261868
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer-Real-world data from a single center in India.
Arora S; Gogia DA; Deo S; Sharma D; Mathur SR
Cancer Treat Res Commun; 2021; 29():100483. PubMed ID: 34710849
[TBL] [Abstract][Full Text] [Related]
19. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]